Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada

Chloé Pronovost-Morgan

Centre for Psychedelic Research, Department of Brain Sciences, Imperial College London, London, UK

Chloé Pronovost-Morgan, Kyle T. Greenway, Leor Roseman, Kirran Ahmad, James Close, David Erritzoe, Orla Mallon, Sara Reed, Balázs Szigeti & Christopher Timmermann

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

Chloé Pronovost-Morgan, Kyle T. Greenway, Houman Farzin & Julien Thibault Lévesque

Department of Psychiatry, McGill University, Montreal, Quebec, Canada

Kyle T. Greenway, Sara de la Salle & Michael Lifshitz

Department of Psychology, University of Exeter, Exeter, UK

Leor Roseman

Michigan Psychedelic Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA

Jacob S. Aday

Yale School of Medicine, Yale University, New Haven, CT, USA

Gabrielle Agin-Liebes

Psychedelic Research and Therapy Development, Adult Psychiatry and Psychotherapy, Psychiatric University Hospital Zurich, Zurich, Switzerland

Helena Aicher

Clinical Research Center for Substance-Assisted Therapy, Division of Medicine, University of Basel, Basel, Switzerland

Helena Aicher

International Center for Ethnobotanical Education Research and Services (ICEERS), Barcelona, Spain

Marc Aixalà & Jerónimo Mazarrasa

Psychedelic Research Lab, Monash University, Melbourne, Victoria, Australia

Simon Amar

Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil

Draulio B. de Araujo & Fernanda Palhano-Fontes

Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Frederick S. Barrett

Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network (UHN), Toronto, Ontario, Canada

Marc Blainey

Psychedelic Participant Advocacy Network (PsyPAN), London, UK

Michael Bourne, Tonie Cox, Ian Roullier & Leonie Schneider

Department of Psychiatry, University Medical Centre Groningen, Groningen, the Netherlands

Joost Breeksema

OPEN Foundation, Amsterdam, the Netherlands

Joost Breeksema

https://Breelove.ca

Kayla Breelove Carter

Alma Viva Institute, São Paulo, Brazil

Cesar Camara

Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA

Nicholas Canby

Vancouver Island University, Nanaimo, British Columbia, Canada

Jimena Chalchi

Psychedelic Lived Experiences, Ottawa, Ontario, Canada

Pedram Daraeizadeh

Center for Psychedelic Drug Research and Education, College of Social Work, Ohio State University, Columbus, OH, USA

Alan K. Davis

University Writing Program, Johns Hopkins University, Baltimore, MD, USA

Neşe Devenot

History of Health and Social Justice, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Erika Dyck

Department of Family Medicine, McGill University, Montreal, Quebec, Canada

Houman Farzin

Social Studies of Medicine, McGill University, Montreal, Quebec, Canada

Phoebe Friesen

Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada

Nicolas Garel

University of Florida Center for Arts in Medicine, Gainesville, FL, USA

Tasha Golden

Heffter Research Institute, Santa Fe, NM, USA

George Greer

Columbia University Medical Center, New York State Psychiatric Institute, New York, NY, USA

Natalie Gukasyan

Fluence, New York, NY, USA

Jeffrey Guss

NYU Grossman School of Medicine, New York University, New York, NY, USA

Jeffrey Guss

University Health Network Psychedelic Psychotherapy Research Group, University of Toronto, Toronto, Ontario, Canada

Emma Hapke

Graduate Program in Science, Technology and Society, Bar Ilan University, Ramat Gan, Israel

Ido Hartogsohn

Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland

Friederike Holze

University of California, San Francisco, San Francisco, CA, USA

Hannes Kettner

Birkbeck, University of London, London, UK

Adam Knowles

The New School for Social Research, The New School, New York, NY, USA

Nicolas Langlitz

International Laboratory for Brain, Music and Sound Research, Centre for Research on Brain, Language and Music (BRAMS-CRBLM), Montreal, Quebec, Canada

Alexandre Lehmann

Michigan Psychedelic Center, University of Michigan, Ann Arbor, MI, USA

Philippe Lucas

The Being Ground, Whitingham, VT, USA

Katherine MacLean

Rory Meyers College of Nursing, New York University, New York, NY, USA

Olivia Marcus

Psychology and Language Sciences, University College London, London, UK

Rosalind McAlpine

Department of Psychiatry, College of Medicine-Tucson, University of Arizona, Tucson, AZ, USA

Francisco Moreno

Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA

Logan Neitzke-Spruill

School of Pharmacy, University of Auckland, Auckland, New Zealand

Tehseen Noorani

Biberist, Switzerland

Peter Oehen

Fundació Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain

Genís Ona

NOSM University, Thunder Bay, Ontario, Canada

Ryan Patchett-Marble & Sayali Tadwalkar

Roots to Thrive, Nanaimo, British Columbia, Canada

Gail Peekeekoot

Psychedelics Research and Therapeutics Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia

Daniel Perkins

Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich, University of Zurich, Zurich, Switzerland

Katrin H. Preller

Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands

Johannes G. Ramaekers

Psychedelic Substances Research Group, Department of Psychiatry and Neurosciences, Charité—Universitätsmedizin Berlin, Berlin, Germany

Dimitris Repantis

Gladstone Psychiatry and Wellness, Baltimore, MD, USA

Brian Richards

Sunstone Therapies, Rockville, USA

William Richards

Céu do Montréal, Montreal, Quebec, Canada

Jessica Rochester

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

James Rucker

South London and Maudsley NHS Foundation Trust, London, UK

James Rucker

School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia

Simon Ruffell

DMT Research Group, Centre for Psychedelic Research, Department of Brain Sciences, Imperial College London, London, UK

James W. Sanders

Hammersmith Medicines Research, London, UK

Thomas Shutte & Hattie Wells

Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA

Balázs Szigeti

MAPS Israel, Hod Hasharon, Israel

Keren Tzarfaty

Faculty of Humanities and Social Sciences, Centre for Interdisciplinary Studies, Athabasca University, Athabasca, Alberta, Canada

Keith Williams

C.P.-M., K.T.G. and L.R. all contributed to project conceptualization, funding acquisition, methodology, investigation, formal analysis, writing of the original paper, and reviewing and editing of the paper. C.P.-M. and K.T.G. wrote the first draft of the explanatory document, and K.T.G. and L.R. reviewed and edited it. C.P.-M. led the project, under the supervision of K.T.G. and L.R. All coauthors listed within the ‘ReSPCT Experts’ consortium contributed as participants of the Delphi consensus process, and to the reviewing and editing of the paper and supplements. All authors approved the final version of the paper and supplements before submission for journal review.